Last reviewed · How we verify
NCT05493371: Emphower PoC
Empagliflozin in Pulmonary Arterial Hypertension
Phase 2 trial testing Empagliflozin 10 MG in Idiopathic Pulmonary Arterial Hypertension in 8 participants. Completed in 1 November 2024.
1 November 2024
Quick facts
| Lead sponsor | Amsterdam UMC, location VUmc |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 1 March 2023 |
| Primary completion | 1 November 2024 |
| Estimated completion | 1 November 2024 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Empagliflozin 10 MG — full drug profile →
Conditions studied
- Idiopathic Pulmonary Arterial Hypertension — all drugs for Idiopathic Pulmonary Arterial Hypertension →
Sponsor
Amsterdam UMC, location VUmc — full company profile →
Who can join
18 and older, any sex, with Idiopathic Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to determine whether conducting a randomized placebo-controlled clinical trial is feasible, safe for the patient and whether the treatment is well tolerated in patients with idiopathic pulmonary arterial hypertension.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.
Weatherald J, Fleming TR, Wilkins MR, Cascino TM, et al · · 2024 · cited 11× · PMID 39209468 · DOI 10.1183/13993003.01205-2024 -
Glycolysis modulation: New therapeutic strategies to improve pulmonary hypertension (Review).
Chen M, Li H, Li Y, Luo Y, et al · · 2024 · cited 8× · PMID 39422043 · DOI 10.3892/ijmm.2024.5439 -
Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs.
Jin Q, Chen D, Zhang X, Zhang F, et al · · 2023 · cited 8× · PMID 37376028 · DOI 10.3390/pharmaceutics15061579 -
New therapies in pulmonary arterial hypertension: Recent insights.
Guglielmi G, Dimopoulos K, Wort SJ. · · 2025 · cited 7× · PMID 39991439 · DOI 10.1016/j.ijcchd.2025.100571 -
An updated review of experimental rodent models of pulmonary hypertension and left heart disease.
Jasińska-Stroschein M. · · 2023 · cited 6× · PMID 38259266 · DOI 10.3389/fphar.2023.1308095 -
The effects of sodium-glucose cotransporter 2 inhibitors on the 'forgotten' right ventricle.
Qu L, Duan X, Chen H. · · 2025 · cited 4× · PMID 39370371 · DOI 10.1002/ehf2.15103
Verify or expand the search:
- PubMed search for NCT05493371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Empagliflozin 10 MG
Trials testing the same drug.
- NCT03867487 — SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease · Phase 2 · not yet recruiting
- NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
- NCT06706791 — Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II · Phase 4 · recruiting
- NCT06473844 — Efficacy of SGLT2 Inhibitors in Adults With Sepsis · NA · recruiting
- NCT06030843 — The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 · Phase 2, PHASE3 · recruiting
Other recruiting trials for Idiopathic Pulmonary Arterial Hypertension
Currently open trials in the same condition.
- NCT06104228 — 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) · Phase 2 · recruiting
- NCT06587074 — Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strat · active not recruiting
- NCT05462574 — Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH) · recruiting
- NCT05584722 — Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals · recruiting
Other Amsterdam UMC, location VUmc trials
Trials by the same sponsor.
- NCT07470697 — Deep Relaxation Using Virtual Reality Intervention Before Surgery for Healthcare Professionals Working in the Operating · NA · not yet recruiting
- NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting
- NCT07155681 — Evaluating Healthcare Professionals' Satisfaction and Stress Mitigation Using Virtual Reality Intervention in Surgical W · NA · not yet recruiting
- NCT06416345 — Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care · NA · recruiting
- NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05493371 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amsterdam UMC, location VUmc
- Last refreshed: 20 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05493371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing